Texas is currently home to 4879 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Recruiting
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from ge... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/07/2025
Locations: Parkland Memorial Hospital, Dallas, Texas
Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatme... Read More
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
06/07/2025
Locations: University of Texas at Arlington, Arlington, Texas
Conditions: Chronic Kidney Diseases
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Recruiting
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Artiva Clinical Trial Site, Arlington, Texas
Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis
Recruiting
In the clinical performance part of this study, prospectively acquired clinician-collected and clinician-instructed, self-collected vaginal swab specimens collected in cobas® PCR Media will be taken from a minimum of 500 symptomatic individuals with a clinical presentation consistent with vaginitis, vaginosis, or both. Additionally, a minimum of 100 asymptomatic individuals will also be enrolled in the study. The cobas® BV/CV assay amplifies and detects the deoxyribonucleic acid (DNA) of pathoge... Read More
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
06/06/2025
Locations: Planned Parenthood Gulf Coast, Houston, Texas
Conditions: Bacterial Vaginosis, Candida Vaginitis
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Recruiting
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Site-103, Austin, Texas
Conditions: Solid Tumor
Cardiovascular Responses in Burn Survivors During Exercise
Recruiting
This project will identify the efficacy of cooling modalities aimed to attenuate excessive elevations in skin and internal body temperatures, and associated indices of cardiovascular stress, during physical activity in well-healed burn survivors. The investigators will conduct a randomized crossover design study. Non-burned control subjects and subjects who experienced burns covering 20% or more of their body surface area will be investigated. Subjects will exercise in heated environmental condi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2025
Locations: Institute for Exercise and Environmental Medicine - Texas Health Presbyterian Hospital Dallas, Dallas, Texas
Conditions: Burn Injury
Abbott Medical - VERITAS Study
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Texas Cardiac Arrhythmia, Austin, Texas
Conditions: Atrial Fibrillation (AF), Stoke
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
Recruiting
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Research Site, Fort Worth, Texas
Conditions: Non-squamous Non-small Cell Lung Cancer
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
Recruiting
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/06/2025
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease, Type 3, Von Willebrand Disease, Type 2B, Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2 and Type 3
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
Recruiting
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in patients with muco-obstructive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: TTS Research, Boerne, Texas
Conditions: Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Retina Research Institute of Texas, Abilene, Texas
Conditions: Wet Age-related Macular Degeneration